Press Releases

The 2023 PDA Annual Meeting, April 3-5, in New Orleans, La., is organized around the theme, “Back to the Future: Learning from The Past in A Patient-Centric World.” The meeting will spotlight the critical connection between our patients and the manufacturing process and enabling a patient-focused mindset on the manufacturing floor.

The Parenteral Drug Association, Inc. (PDA) and RX Global today announced the renewal of their Premier Association Sponsorship agreement for INTERPHEX 2023, taking place April 25-27, 2023, at the Javits Center in New York City. This is the tenth year PDA has served as a Premier Association Supporter.

PDA Announces the Volunteer Members of its 2023 Board of Directors and Officers

SmartSkin discussed manufacturing and quality assurance issues at the 2022 PDA/FDA Joint Regulatory Conference in Washington earlier this month and showcased its latest product innovations to PDA and FDA members. SmartSkin will also be attending the upcoming PDA Universe of Pre-Filled Syringes and Injection Devices show in Palm Springs, CA, October 18-19.

The largest conference/exhibition dedicated to this critical technology for the delivery of biological and traditional medicines returns to in-person meeting in 2022

Richard M. Johnson concludes an eventful and successful 13-year term at PDA's helm, handing the reins to Glenn E. Wright, PDA COO.

This year’s PDA/FDA Joint Regulatory Conference will emphasize the role of implementing effective quality systems to ensure an ongoing state of control throughout the pharmaceutical product lifecycle by vigilantly managing quality risks. The roles of robust systems, facilities, processes, raw material quality, supplier relationships, industrial modernization, and quality risk management will be emphasized.

Ascendis A/S and Phillips-Medisize A/S received PDA's Innovation Award for the SKYTROFA® Auto-Injector. The Stevanato Group and Bexson Biomedical earned the the Partnership Innovation Award for the innovation Pain Management Therapy through On-Body Injector System.

Packed audience filled the seats of the plenary session and the lanes of the exhibit hall.

The Parenteral Drug Association (PDA) announces senior regulatory experts to speak during opening session of the 2022 PDA Annual Meeting, the first full in-person signature event held by PDA since 2019. The PDA Annual Meeting takes place at the Hyatt Regency in Dallas, Tx., April 4-6.

The Parenteral Drug Association (PDA) today announced the availability of ANSI/PDA Standard 02-2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing: An Introduction and Best Practices Approach on How to Prepare, Cryopreserve, and Recover Cells, Cell Lines, and Cell-Based Tissue Products.

The Parenteral Drug Association (PDA) today announced the results of the 2021 Board of Directors Election for the term beginning January 1, 2022.

The Parenteral Drug Association (PDA) today announced the winners of the 2021 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2021 PDA Universe of Pre-Filled Syringes and Injection Devices.

The Parenteral Drug Association (PDA) today announced the availability of its newest membership type, the Early Career Professional.

The Parenteral Drug Association (PDA) today announced the availability of industry standard, ANSI/PDA Standard 05-2021 Consensus Method for Rating Filters for Mycoplasma, available now for purchase in the PDA Bookstore.

The Parenteral Drug Association, Inc. (PDA) has announced that Glenn Wright, Vice President of Scientific and Regulatory Affairs, was named the Chairman of the Product Quality Research Institute’s (PQRI) Board of Directors. Mr. Wright has participated in PQRI since 2003.

The Parenteral Drug Association (PDA) announced the beginning of its 75th Anniversary celebration. The 2021 PDA Annual Meeting (15–17 March) and the Honor Awards Ceremony (24 March), both virtual online events, served as the official launch of the diamond anniversary.

The Parenteral Drug Association (PDA) announced the availability of ANSI/PDA Standard 04-2021 Phage Retention Nomenclature Rating for Small and Large Virus-Retentive Filters.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced it has signed an agreement to collaborate with Deloitte Consulting, LLP and the U.S. FDA’s Compounding Quality Center of Excellence to provide training to large pharmaceutical compounders in a variety of Good Manufacturing Practices (GMP)-related functions critical to improving the overall quality of compound drugs.

Enables Access to Healthcare Coverage for their members with Immediate Savings and Simple Enrollment